HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...

Catherine Isted, an experienced healthcare CFO with over 25 years in life sciences, appointed as CFO effective February 24, 2025Current CFO ...

AstraZeneca’s Imfinzi (durvalumab) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Produc ...

Imfinzi recommended for approval in European Union for the treat of adults with limited-stage small cell lung cancer ...

The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...

EU agencies unite to tackle azole fungicide resistance in Aspergillus fungi: Amsterdam, The Netherlands Monday, February 3, 2025, 17:00 Hrs [IST] For the first time, t ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...

The European Medicines Agency (EMA) announced on Monday that it will be discontinuing its presence on X, opting instead to utilize rival platform Bluesky.

Britain's relationship to the European Court of Justice (ECJ) is in the news. But what is the ECJ and what does it do? We answer some of the key questions. What is the European Court of Justice?

The European Medicines Agency (EMA) has decided to stop using the social media platform X due to content concerns and will instead use Bluesky. This move aligns with other organizations stepping back ...

AMSTERDAM (Reuters) - The European Medicines Agency (EMA) said on Monday it would no longer post on X and would use rival Bluesky instead, becoming the latest organisation to quit a social media ...